Abstract
What are the resources needed by clinical pharmacology to test drugs in ways that model how the practitioner achieves optimal effectiveness and safety with each patient? I describe the applications of test-retest standard error of measurement, clinical decision rules, means or other statistical summaries of observations, clinical trial designs that use each patient as her own control, and methods to control observer and site variance as steps for developing a CT tested model for optimal clinical uses of an Alzheimers drug by a practitioner. Many investigators and clinicians have been concerned with clinical judgments being scientifically uncontrolled and unsystematic. The methods I describe demonstrate how clinical trials can be used to overcome these limitations in current patient care. “Darwin showed that one simply could not understand evolution as long as one accepted essentialism. Species and populations are not types, they are not essentialistically defined classes, but rather are biopopulations composed of genetically unique individuals” E. Mayr [1].
Keywords: Alzheimer disease, Darwinian Biological Thinking, random measurement errors, standard error of measurement, Placebo
Current Alzheimer Research
Title: Lessons from Darwin: 21st Century Designs for Clinical Trials
Volume: 4 Issue: 4
Author(s): Robert E. Becker
Affiliation:
Keywords: Alzheimer disease, Darwinian Biological Thinking, random measurement errors, standard error of measurement, Placebo
Abstract: What are the resources needed by clinical pharmacology to test drugs in ways that model how the practitioner achieves optimal effectiveness and safety with each patient? I describe the applications of test-retest standard error of measurement, clinical decision rules, means or other statistical summaries of observations, clinical trial designs that use each patient as her own control, and methods to control observer and site variance as steps for developing a CT tested model for optimal clinical uses of an Alzheimers drug by a practitioner. Many investigators and clinicians have been concerned with clinical judgments being scientifically uncontrolled and unsystematic. The methods I describe demonstrate how clinical trials can be used to overcome these limitations in current patient care. “Darwin showed that one simply could not understand evolution as long as one accepted essentialism. Species and populations are not types, they are not essentialistically defined classes, but rather are biopopulations composed of genetically unique individuals” E. Mayr [1].
Export Options
About this article
Cite this article as:
Becker E. Robert, Lessons from Darwin: 21st Century Designs for Clinical Trials, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788828
DOI https://dx.doi.org/10.2174/156720507781788828 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Exploring the Links between Obesity and Alzheimers Disease (Guest Editor: Suzana S. Petanceska) ]
Current Alzheimer Research Who Should Receive Low-Dose Aspirin for Pre-eclampsia Prevention? Sorting through the Meta-Analyses
Current Women`s Health Reviews High Catalytic Activity of Pd Nanoparticles Synthesized from Green Alga Chlorella vulgaris in Buchwald-hartwig Synthesis of N-Aryl Piperazines
Current Organocatalysis Neurological Disorder Drug Discovery from Gene Expression with Tensor Decomposition
Current Pharmaceutical Design Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry The Role of Fatty Acids in the Regulation of Cerebral Vascular Function and Neuroprotection in Ischemia
CNS & Neurological Disorders - Drug Targets IFN-γ and TNF-α Gene Polymorphisms in Multiple Sclerosis Patients in Northwest Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease
Current Molecular Pharmacology Oral Fluid vs. Urine Analysis to Monitor Synthetic Cannabinoids and Classic Drugs Recent Exposure
Current Pharmaceutical Biotechnology Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer’s Disease Treatment
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part I Nitric Oxide Synthesis and Action
Vascular Disease Prevention (Discontinued) Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity
Current Neuropharmacology Targeting Brain Nicotinic Acetylcholine Receptors to Treat Major Depression and Co-Morbid Alcohol or Nicotine Addiction
CNS & Neurological Disorders - Drug Targets Emerging Therapeutic Potential of Whey Proteins and Peptides
Current Pharmaceutical Design The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
Current Cardiology Reviews Intrathecal Administration of Melatonin Ameliorates the Neuroinflammation- Mediated Sensory and Motor Dysfunction in A Rat Model of Compression Spinal Cord Injury
Current Molecular Pharmacology The Relationship Between Diabetes Mellitus, Geriatric Syndromes, Physical Function, and Gait: A Review of the Literature
Current Diabetes Reviews Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
CNS & Neurological Disorders - Drug Targets